Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
World game at war: why some European nations have threatened a World Cup boycott 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
CAMBRIDGE, Mass., April 23, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, will report first quarter 2018 financial results after the Nasdaq Global Market closes on Thursday, May 3, 2018. Subsequently, at 4:30 p.m. Eastern Time, the Company will host a conference call to discuss its first quarter 2018 financial results and to provide a corporate update.
The conference call may be accessed by dialing 844-534-7313 for domestic callers and +1-574-990-1451 for international callers. The passcode for the call is 2798939. Please specify to the operator that you would like to join the "Sarepta First Quarter 2018 Earnings Call". The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
